Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	0.42	0.92	4.17	2.48	4.09	-
Cash & Short-Term Investments	0.42	0.92	4.17	2.48	4.09	-
Cash Growth	-91.08%	-77.99%	68.02%	-39.36%	-	-
Receivables	-	-	-	0.27	-	-
Prepaid Expenses	0.52	0.72	0.29	-	0.83	-
Total Current Assets	0.94	1.64	4.45	2.75	4.92	-
Long-Term Deferred Charges	-	-	-	0.28	-	-
Other Long-Term Assets	1.5	1.5	-	-	-	-
Total Assets	2.44	3.14	4.45	3.03	4.92	-
Accounts Payable	0.01	0	-	-	-	-
Accrued Expenses	4.25	2.98	0.14	8.85	0.03	-
Current Portion of Leases	0.01	0	0	0.02	-	-
Current Income Taxes Payable	0	0	0.04	-	-	-
Other Current Liabilities	0	0.01	0	0.88	0.92	-
Total Current Liabilities	4.28	3	0.18	9.76	0.95	-
Other Long-Term Liabilities	-	-	-	0.01	0.01	-
Total Liabilities	4.28	3	0.18	9.77	0.96	-
Common Stock	0	0	0	0	0	-
Additional Paid-In Capital	24.8	24.64	24.12	0.45	0.03	-
Retained Earnings	-26.03	-23.93	-19.5	-12.19	-1.07	-
Treasury Stock	-0.6	-0.57	-0.35	-	-	-
Total Common Equity	-1.83	0.14	4.27	-11.74	-1.04	-
Shareholders' Equity	-1.83	0.14	4.27	-6.74	3.96	-
Total Liabilities & Equity	2.44	3.14	4.45	3.03	4.92	-
Total Debt	0.01	0	0	0.02	-	-
Net Cash (Debt)	0.41	0.91	4.16	2.46	4.09	-
Net Cash Growth	-91.29%	-78.06%	69.36%	-39.90%	-	-
Net Cash Per Share	0.01	0.03	0.15	8.04	-	-
Filing Date Shares Outstanding	36.17	36.17	36.19	35.2	0.18	-
Total Common Shares Outstanding	36.17	36.19	36.29	4.06	0.18	-
Working Capital	-3.33	-1.36	4.27	-7.01	3.97	-
Book Value Per Share	-0.05	0.00	0.12	-2.89	-5.91	-
Tangible Book Value	-1.83	0.14	4.27	-11.74	-1.04	-
Tangible Book Value Per Share	-0.05	0.00	0.12	-2.89	-5.91	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q